US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

3.630 -0.270 (-6.92%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Unusual volume stocks in Thursday's session ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences (NASDAQ:TLSI) Swings to Surprise Net Profit in Q1, But Revenue Miss Tempers Outlook ↗
Via Chartmill
News headline image
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference ↗
TriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing... 
Via MarketBeat
News headline image
TriSalus Life Sciences Q2 Earnings Call Highlights ↗
TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system... 
Via MarketBeat
Topics Earnings
News headline image
TriSalus Life Sciences Reports Second Quarter 2026 Results
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
From TriSalus Life Sciences
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
TriSalus (TLSI) Q1 2026 Earnings Transcript ↗
TriSalus (TLSI) Q1 2026 Earnings Transcript 
Via The Motley Fool
Wednesday's session: top gainers and losers ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
TriSalus Life Sciences Q1 Earnings Call Highlights ↗
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 Next >